This indicates low potency for this drug on IL-17 production, confirmed by the high IC35 values >0.25 μM; this contrasts sharply with low nanomolar tofacitinib IC35 values for other cytokines (see Table 2), and suggests that JAK inhibitors may not reduce IL-17-driven responses in asthma. This evidence concerns the gene IL17A and asthma.